U.S. Vaccine Plan Relied On a Problematic Factory.

The article reports on challenges faced by Emergent BioSolutions in its production of Covid-19 vaccines developed by AstraZeneca and Johnson & Johnson as of April 2021. Topics include the scheduled destruction by the company of around 150 million doses of vaccines due to contamination, the alleged poor manufacturing practices at the Emergent facility, and the comment by pharmaceutical quality expert Doctor Ajaz Hussain on Emergent's shortcomings.